Objective. The efficacy of omalizumab in severe asthma has been widely demonstrated. The
main objective of this study was to evaluate the efficacy and tolerability of omalizumab in a …

Background: There are limited pediatric data about the use of omalizumab, especially the
effectiveness and safety of omalizumab in the real-world management of allergic asthma …

Objective. Omalizumab is a biological treatment for difficult-to-treat allergic asthma. Its
mechanism of action relies on impeding the binding of immunoglobulin E (IgE) to specific …

Background: The health, economic and societal burden of asthma is considerable, and is
greatest in patients with severe asthma, particularly when inadequately controlled. Real‐life …

Omalizumab is a humanized monoclonal anti-IgE antibody recently approved for the
treatment of severe allergic asthma. This drug inhibits allergic responses by binding to …

Introduction: The evolution in immunological methods used to assess human allergic
diseases has led to the identification of immunoglobulin E (IgE) as a diagnostic biomarker …

Background: We have previously shown that omalizumab, a recombinant humanized
monoclonal anti-IgE antibody, reduces asthma exacerbations and decreases inhaled …

OBJECTIVE: To review the pharmacology, efficacy, and safety of omalizumab, focusing on
the treatment of allergic asthma. DATA SOURCES: A MEDLINE search (1966—November …

Background Omalizumab is indicated for patients with moderate-to-severe allergic asthma
with inadequately controlled symptoms. Objective We evaluated the association between …

Objective. Approved by the FDA in 2003, omalizumab is the first recombinant humanized
monoclonal anti-immunoglobulin E antibody developed for the treatment of allergic asthma …